Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a research report released on Friday morning.

A number of other equities research analysts have also recently weighed in on CPRX. HC Wainwright reissued a buy rating and issued a $26.00 price target on shares of Catalyst Pharmaceuticals in a research report on Monday, June 3rd. Citigroup boosted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a buy rating in a report on Friday. Truist Financial raised their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a buy rating in a research note on Friday. Finally, Oppenheimer reiterated an outperform rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of Buy and a consensus price target of $28.83.

Catalyst Pharmaceuticals Trading Up 1.0 %

CPRX stock traded up $0.18 during trading on Friday, hitting $18.48. 2,888,357 shares of the company’s stock were exchanged, compared to its average volume of 1,290,174. The business has a 50-day moving average price of $16.14 and a two-hundred day moving average price of $15.60. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of 34.22 and a beta of 0.70. Catalyst Pharmaceuticals has a 52-week low of $11.55 and a 52-week high of $18.99.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. The business had revenue of $98.51 million during the quarter, compared to the consensus estimate of $97.24 million. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. On average, equities research analysts anticipate that Catalyst Pharmaceuticals will post 1.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the completion of the sale, the insider now directly owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the business’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $16.07, for a total value of $121,183.87. Following the transaction, the insider now directly owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Richard J. Daly sold 17,323 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $15.97, for a total transaction of $276,648.31. Following the transaction, the chief executive officer now owns 234,824 shares of the company’s stock, valued at approximately $3,750,139.28. The disclosure for this sale can be found here. Insiders have sold a total of 110,197 shares of company stock valued at $1,777,560 over the last quarter. 11.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $31,000. GAMMA Investing LLC grew its holdings in Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 819 shares during the period. CWM LLC raised its position in Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at $70,000. Finally, Nisa Investment Advisors LLC boosted its position in shares of Catalyst Pharmaceuticals by 306.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 3,829 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.